CLINICAL TRIALS, STUDIES, REGISTRIES, DATA

Dr. Joel Braunstein, CEO of C2N Diagnostics, says, “This research increases the growing body of evidence that demonstrates high clinical utility with blood biomarkers, which is bringing important advancements to the field. Too often, patients face a complex and delayed diagnostic journey when dealing with new cognitive concerns. High-performance testing with our PrecivityAD2 blood test has the potential to provide clarity and shorten that diagnostic journey, while significantly elevating healthcare quality.”

Interactive Response Technology (IRT) helps clinical trial sites and sponsors manage both participant randomization and trial supply management (RTSM). What was once a manual,...

The GAMEFILM Registry will enroll approximately 120 NFL alumni. The Registry will leverage coronary computed tomography angiography (CCTA) imaging and insights from the HeartFlow ONE platform (HeartFlow FFRCT and Plaque Analysis) to collect observational data with the goal of better understanding CAD prevalence, risk factors, severity, and treatment protocols among retired athletes.

“We are delighted to have treated the first patients – this is a significant milestone in our clinical trial and our mission to develop curative treatments for critically ill cancer patients. We have an outstanding trial team and look forward to the upcoming results,” says Samuel Svensson, CEO of Neogap Therapeutics.

The focal point of the study is the growing role of machine learning in wearables. Peer-reviewed research from PubMed, MDPI, ScienceDirect, and other leading sources for scientific and medical research proves that monitoring vital signs, such as heart rate, can support the early detection of health risks and potentially reduce reliance on traditional in-person medical examinations.

“These findings demonstrate that mental health factors like anxiety play a critical role in the clinical course of IBD,” said Beth Houck, CEO, SonarMD “By identifying and addressing psychological contributors, we can refine value-based care models to better support patients with chronic digestive diseases. Integrated care models that incorporate mental health screening and interventions should be considered a standard for high-quality IBD care.”

Hugh Salter, Chief Scientific Officer at Anocca, elaborated, "KRAS is an immensely important target in many cancer types, but has to date been challenging to address. KRAS mutations are a hallmark of PDAC, which is among the most difficult to treat cancers, and we believe TCR-T cell therapies and, in particular, our VIDAR-1 assets can be effective in addressing this target and providing a new solution in an indication with high unmet medical need.”